Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
AJNR. American Journal of Neuroradiology
|
December 11, 2012
Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?
S Fellah, D Caudal, A M De Paula, et al.
Neuro-Chirurgie
|
September 2, 2008
[Prognostic implications of biologic markers in intracranial meningiomas: 120 cases]
P Metellus, I Nanni, C Dussert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 22, 2003
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
M J van den Bent, O Chinot, W Boogerd, et al.
Neurology
|
July 28, 2004
Initial chemotherapy in gliomatosis cerebri
M Sanson, S Cartalat-Carel, S Taillibert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
M J van den Bent, M J B Taphoorn, A A Brandes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2014
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†
B Chauffert, L Feuvret, F Bonnetain, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2019
Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study
R Ursu, L Thomas, D Psimaras, et al.
Revue Neurologique
|
June 21, 2008
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]
S Guiu, S Taillibert, O Chinot, et al.
Neuro-Chirurgie
|
May 22, 2017
[Adult intramedullary gliomas]
C Campello, F Parker, S Slimani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2019
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†
H Ghesquieres, M Chevrier, M Laadhari, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
AJNR. American Journal of Neuroradiology
|
December 11, 2012
Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?
S Fellah, D Caudal, A M De Paula, et al.
Neuro-Chirurgie
|
September 2, 2008
[Prognostic implications of biologic markers in intracranial meningiomas: 120 cases]
P Metellus, I Nanni, C Dussert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 22, 2003
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
M J van den Bent, O Chinot, W Boogerd, et al.
Neurology
|
July 28, 2004
Initial chemotherapy in gliomatosis cerebri
M Sanson, S Cartalat-Carel, S Taillibert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
M J van den Bent, M J B Taphoorn, A A Brandes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2014
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†
B Chauffert, L Feuvret, F Bonnetain, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2019
Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study
R Ursu, L Thomas, D Psimaras, et al.
Revue Neurologique
|
June 21, 2008
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]
S Guiu, S Taillibert, O Chinot, et al.
Neuro-Chirurgie
|
May 22, 2017
[Adult intramedullary gliomas]
C Campello, F Parker, S Slimani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2019
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†
H Ghesquieres, M Chevrier, M Laadhari, et al.
Page
of 6